Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer

NCT04394858 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

46

Enrollment

NIH

Sponsor class

Conditions

Advanced Adrenal Gland Pheochromocytoma
Advanced Paraganglioma
Metastatic Adrenal Gland Pheochromocytoma
Metastatic Paraganglioma
Stage III Adrenal Gland Pheochromocytoma and Sympathetic Paraganglioma AJCC v8
Stage IV Adrenal Gland Pheochromocytoma and Sympathetic Paraganglioma AJCC v8
Unresectable Adrenal Gland Pheochromocytoma
Unresectable Paraganglioma

Interventions

PROCEDURE: Biospecimen Collection
PROCEDURE: Computed Tomography with Contrast
PROCEDURE: Magnetic Resonance Imaging
DRUG: Olaparib
OTHER: Quality-of-Life Assessment
DRUG: Temozolomide

Sponsor

National Cancer Institute (NCI)